The US firm is getting its hands on eight programs from two of the world's leading drug makers, seeing an opportunity in areas such as antibiotics where solutions may be more likely to come from biotech rather than big pharma.
Boston Pharmaceuticals Inc. is the latest beneficiary of big pharma companies paring down their R&D portfolios, after getting hold of early-stage assets from GlaxoSmithKline PLC and Novartis AG.
First up, Boston has in-licensed five programs from GSK, which include two Phase II-ready candidates
Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.
Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
